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ABSTRACT 
With the advancement in modern pharmaceutical technologies, Nanotechnology is the one of the most establish technology which is 
used to improve the therapeutic index and to overcome the formulation challenges of poorly water-soluble compounds. 
Nanocrystals, in nano range, is the interesting approach for poorly soluble drugs. Due to the small size, increased surface area 
enhanced the dissolution rate and solubility of drug. In this paper, current technologies and methods in nanocrystal preparation, 
stabilization, pharmaceutical applications and limitations of nanocrystal are reviewed. 
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INTRODUCTION 
Now days, the most important issue in drug discovery 
and development is the poor solubility. Lots of new 
chemical entities shows significant therapeutic effects, 
better efficiency but their clinical applications are 
restricted due to the poor water solubility. These types 
of new chemical entities in Biopharmaceutics 
Classification System (BCS) belongs to BCS class II or 
class IV.
1 
Therefore various types of approaches have been 
established to overcome the problem of low aqueous 
solubility. These approaches are - Salt formation, Co-
solvent, Complexation and Solid state manipulation, 
Emulsions, Surface active agents, Micronization.
2, 3 
The classic formulation approach is the micronization 
meaning the transfer of drug powders into the size range 
between typically 1-10μm. . However, in many cases 
they cannot solve the bioavailability problem. A 
consequent next step was to move from micronization to 
nanonization. 
‘Nanonization’ i.e., conversion of micronized particles 
to nano-sized particles is a logical step forward. Various 
nanonization strategies have emerged to increase the 
dissolution rates and bioavailability of numerous drugs 
that are poorly soluble in water. These strategies include 
increasing the surface area, changing the crystalline 
forms and designing novel nanomaterials that can act as 
carriers for controlled release.
3, 4 
Drug nanocrystals represent a novel and versatile 
approach to improve solubility and bioavailability of the 
poorly soluble drugs. Surface modifications (increased 
surface area) of drug particles by nanocrystal approach 
impart a feature of improved adhesiveness to the 
surfaces. This pioneering nanocrystal technology can be 
combined with the conventional dosage forms to further 
add an advantage to the drug therapy.
5
 
Definition: Drug Nanocrystal    
Nanocrystals are crystalline nanoparticles with size 
ranging from 200 to 500 nm stabilized by surface 
stabilizers. They increase the saturation solubility, 
dissolution rate and probably the mucoadhesion 
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resulting in improved oral bioavailability of drugs 
exhibiting dissolution rate dependent bioavailability.
6 
Drug nanocrystals constitute a versatile formulation 
approach to enhance the pharmacokinetic and 
pharmacodynamic properties of poorly soluble drugs. 
The formulation simplicity and production scaling 
flexibility along with their intrinsic small particle size 
and large surface area make NCs stand a way unique not 
just among the pharmaceuticals but also among other 
nanoparticles.
7,8 
 
 
                                                               Figure 1: Nanocrystals with surface modification 
Advantages 
 
Figure 2: Advantages of nanocrystals 
Limitations 
¤ Limited to only BCS II class drug only. 
¤ High cost instruments are required for production of drug nanocrystal that increase the cost of dosage form. 
¤ The formation of nanocrystals and their stability is depend on the molecular structure of the drug, so only certain 
classes of compound will qualify.
9
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Properties: 
Increase of dissolution velocity by surface area enlargement: 
   
 
 
 
The dissolution rate is proportional to the surface area available for dissolution as described by the Noyes–Whitney 
equation:  
                                                          
              
 
 
Where:                                         
              dc/dt   =     dissolution velocity 
              D        =      diffusion coefficient 
              A        =      surface area 
              cs           =      saturation solubility 
              cx          =      bulk concentration 
              h       =      diffusional distance over which the concentration gradient occurs.
10, 11 
 
 Increase in saturation solubility : 
The saturation solubility cs is a constant depending on 
the compound, the dissolution medium and the 
temperature. However, below a critical size of 1–2 µm, 
the saturation solubility is also a function of the particle 
size. It increases with decreasing particle size below 
1000 nm. Therefore, drug nanocrystals possess 
increased saturation solubility. 
The Ostwalde Freundlich equation directly describes the 
relation between the saturation solubility of the drug and 
the particle size 
                     
Where:  
            Cs= saturation solubility, 
             C� = solubility of the solid consisting of large 
particles, 
             r = interfacial tension of substance, 
             V = molar volume of the particle material, 
             R = gas constant, 
             T = absolute temperature 
             r = radius of particle  
 An increased adhesiveness to surface/cell 
membranes: 
Increased adhesiveness is also due to the increased 
surface area available for interaction. The increased 
adhesiveness of nanomaterials is usually due to an 
increased contact area of small particles versus large 
particles (at identical total particle mass). Similar to 
other nanoparticles, drug nanocrystals show an 
increased adhesiveness to tissue which lead to an 
improvement of oral absorption of poorly soluble drugs 
apart from the increased saturation solubility and 
dissolution rate 
Properties of nanocrystals 
1 – Size below 1 μm 
2 – 100% drug, no carrier 
3 – Generally needed to be stabilized 
4 – Crystalline or amorphous structure 
5 – Increase of dissolution velocity 
6 – Increase in saturation solubility 
7 – Amorphous particle state offers advantages 
 
Stabilization of drug nanocrystals 
Drug nanocrystals are nanosized solid drug particles 
surrounded by a stabilizer layer. Often nanocrystals are 
considerably easy to produce, but the stability and the 
selection of stabilizer is the most challenging and 
critical step. Stabilizers stabilize the newly formed drug 
nanocrystals, but they also have an important role in 
further formulation and they even affect the drugs 
bioavailability. Mostly, the stabilizer selection is based 
purely on the requirement of physical stability, e.g., 
maintaining the nanosized particle size as long as 
possible after the formation of drug nanocrystals.
12
 
The massive surface area of nanocrystals results in 
sufficiently high free energy or surface charge that 
might cause attraction or agglomeration. Small sized 
nanocrystals sometimes raise the solubility of drug 
beyond the saturation point which promotes 
recrystallization into larger particles; also known as 
     Size      Surface area    Dissolution velocity                Bioavailability 
Kaur et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2018; 8(5):118-129          
ISSN: 2250-1177                                                                             [121]                                                                             CODEN (USA): JDDTAO 
Ostwald ripening. These processes ultimately lead to 
irreversible loss of formulation integrity.
12, 13 
Agglomeration is prevented by the presence of 
stabilizers in the nano-formulation. Stabilizers can 
spontaneously adsorb on and cover the newly formed 
particle surface to (a) decrease the free energy of system 
and interfacial (surface) tension of particles; (b) form a 
dense hydrophilic layer around hydrophobic particles, 
provide steric hindrance and steep repulsions between 
the particles (steric stabilization); (c) charge the particle 
surface if the stabilizer has ionizable groups, which 
increase the repulsive force (electrostatic stabilization); 
(d) combine the steric and electrostatic stabilization.
14 
 
Aggregation and Collision mechanism 
 
 
 
 
 
 
 
 
 Perikinetic aggregation: - If the collisions are 
caused by Brownian motion,the process is called 
perikinetic aggregation and is solely driven by 
diffusion. Small particles in colloidal suspensions 
continuously undergo Brownian motion. These 
particles collide with each other and stick together 
due to attractive forces acting between them. 
 Differential sedimentation: - Particles of different 
diameters settle at different velocities causing the 
faster moving particles to collide with the slower 
moving particles resulting in aggregation. 
 Orthokinetic aggregation: - Such collisions occur 
under conditions of shear, either by stirring or by 
flow. Orthokinetic aggregation is dependent on the 
initial particle size and velocity gradient, but is 
independent of temperature.
13,14 
 
Classification of the stabilizers 
                                                                                     Stabilizers 
 
 
 
 
 
 
 
 
 
 
 
PVP   =    Povidone                                      PVA     = Polyvinyl alcohol,         TPGS  = D-α-tocopheryl polyethylene glycol succinate                      
PEG  =    Polyethylene glycol                      HPMC = Hypromellose Cellulose PEO   = Polyethylene oxide                     
HPC  =    Hydroxypropyl cellulose             HEC    = Hydroxyethyl Cellulose  PPO   = Polypropylene oxide 
NaCMC = Carboxymethylcellulose sodium,     SD   = Docusate sodium 
SLS       = Sodium lauryl sulfate                         PEI   = Polyethylene imine      
 Aggergation 
Mechanism 
Perikinetic aggregation 
Differential sedimentation 
Orthokinetic   aggregation 
Synthetic Semi synthetic 
Copolymericic Ionic Non-ionic 
PVP, PVA PVA-PEG 
graft Co-
polymers 
NaCMC, Na 
alginate, 
chitosan, PEGs 
Surfactants 
Ionic Non-inonic 
SD, SLS, PEI 
Food-proteins, 
Amino acids, Co-
polymers 
Linear 
HPMC, HPC, HEC 
Tweens, Poloxamers, 
TPGS, Block polymer 
of PEO-PPO-PEO 
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Mechanism of the stabilization 
 
Figure 4: Mechanism 
 
Electrostatic Stabilization: - Adsorption of the ions to 
the surface results in mutual repulsive forces between 
the particles. Increase in the ionic strength influence the 
repulsive force and reduce the thickness of electrical 
double layer which leads to a decrease in the repulsion 
potential of the particles. 
Steric Stabilization: Adsorption of the non-ionic 
amphipathic particles on the surface of the particles. In 
the case of the steric stabilization, the adsorbed polymer 
does not possess electrostatic charge. 
Electrosteric Stabilization: - Electrsteric stabilization is 
the combination of both above mentioned stabilizations. 
Electrosteric stabilization can also be provided by using 
a combination of two different stabilizers, an ionic 
surfactant and a polymer, respectively.
12, 14 
 
Table 1: Mechanism of Stabilization
 
Mechanism of stabilization Stabilizing agent Techniques 
Electrostatic SLS, Nanoprecipitation and Bead miling 
Steric HPMC,PVA K15, Poloxamer 188, 
Poloxamer 407 
Antisolvent precipitation, Ball milling,High 
pressure homogenization, 
Electrosteric PVP K30, SLS, Poloxamer 188, 
Lecithin 
High pressure homogenization, Emulsion 
diffusion, 
 
 
Figure 5: A suitable concentration of stabilizer should be present in the system to produce nanosuspensions with small 
particle size and to assure colloidal stability. Excess stabilizer should be avoided to prevent solubilization and increase 
of particle size due to Ostwald ripening  
 
 
 
Stabilization 
Electrostatic 
Stabilization 
Electrosteric 
Stabilization 
Steric 
Stabilization 
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Selection of the stabilizer: 
 
                                                       
                                                 
 
                                             
 
 
                                                     
 
                                                
 
 
 
                                                                 
                                                      
                                                          
 
 
 
 
 
  
 
 
 
                                                                                                   
  
   Selection of the stabilizers 
Drug related 
parameters 
Stabilizer related parameters 
Dispersion medium 
related parameters 
Zeta potential: a measure of 
the magnitude of the 
interaction between colloidal 
particles. The zeta potential 
caused by stabilizer is 
affected by the pH of 
dispersion medium, 
conductivity, concentration of 
drug in dispersion. 
 ± 30mV for 
electrostatically & mini. 
± 20 mV for others. 
Log P and enthalpy of 
melting: a stable 
Nanosuspension should have 
the similar log P value of the 
drug and stabilizer. 
 Low enthalpy effect the 
stabilization of 
formulation. 
Drug solubility in a 
stabilizer solution: Ostwald 
ripening refers to the growth 
of larger particles at the 
expense of smaller particles. 
It occurs due to the faster rate 
of the solubilization of 
smaller particles because of 
their larger surface area and 
smaller curvature relative to 
the larger particles 
 
Molecular weight: The chain 
length of the polymers should be 
large enough to overcome the van 
der Waals forces of attraction. 
 Polymers ranging from 
approximately 5000 to 
25000 g/mol are suitable. 
Affinity of the drug: Higher affinity         
faster adsorption   
Surface energy: Surface energy of the 
stabilizer and drug leads to minimal 
particle size deviation. 
Viscosity: a high viscosity leads to    
the diffusion velocity and ensures the 
stability of the colloidal system. 
Concentration of the stabilizers: 
optimum concentration is required for 
stability. 
 Affects adsorption efficiency. 
 Concentration should be less 
than CMC for electrostatic 
stabilization. 
 Higher concentration affects 
electrical double layer and 
leads to destabilization. 
 
Temperature of the 
medium: Affect the affinity 
of the stabilizer. 
 temperature   the 
dynamic viscosity 
and the diffusion 
coefficient 
pH of the dispersion 
medium: The pH causes 
alterations in ionizability of  
electrostatic and static 
stabilization. 
 Affects the 
stabilization 
potential. 
Hydrophobicity: Hydrophobicity 
of drug and stabilizer has 
combined effect on nanocrystal’s 
stability. 
 HLB scale is used. 
 HLB numbers are low for 
hydrophobic surfactants and 
high for hydrophilic 
surfactants. 
 For effective stabilization, 
hydrophobic content of 
stabilizer>15mol% 
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Preparation of nanocrystals       
                                            
       
 Two basic approaches are involved in production of nanocrystals, the bottom–up technologies (controlled 
precipitation/ crystallization) and the top–down technologies, nanonizing (large-size drug powder to be reduced in size, 
e.g. by mechanical attrition). However, the combination techniques, combining a pre-treatment with a subsequent size 
reduction step are also being employed.
15, 16
 
     Top – down method: In this technique large crystalline particles are reduced into small particles by shear 
forces. 
Media milling:                   
Drug + water + surfactant + milling media 
 
Add into the milling chamber 
 
Generation of the shear force which reduce the particle size 
 
Milling media contains Zirconium oxide, glass and 
polystyrene beads etc. The mill consists of the milling 
chamber, milling motor, milling pearls and recirculation 
chamber. 
Process parameters: Amount of milling media and 
drug, rotation speed and time. 
Merits:   
 Low batch to batch variations 
 have low particle size distribution 
 High efficiency of drug loading                                                                                                                                                                        
 
Demerits: 
 Impurities in milling media is major concern 
 Intensive-energy use with long milling times16,17,18 
High pressure homogenization (HPH): High energy 
disintegration process which use high energy to reduce 
size. In this method, drug suspension is passed through a 
narrow gap of 25 μm results in formation of cavitation, 
collision among the particles and high shear force 
leading to size reduction.  Two homogenizer types 
normally applied are the piston-gap homogenizer and 
microfluidizer homogenizer. 
 
Nanocrystal Production techniques 
Top-Down 
Media 
milling 
High pressure 
homogenization 
Lyophilization 
Spray drying 
Piston cap 
Micro-
Fluidization 
Bottom up 
Precipitation 
Solvent-anti-
solvent addition 
Precipitation in 
supercritical 
fluid 
Solvent removal 
process 
Spray freezing in 
liquid 
Spray drying 
Freeze drying 
Evaporative 
precipitation into 
aqueous 
solution(EPAS) 
Combination 
Nano Edge 
technology 
Smart crystal 
Spray drying with 
HPH (H42) 
Lyophilization  
with 
HPH(H96) 
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Merits: 
 used for the production of dilute as well as 
concentrated nanosuspension with low particle size 
distribution 
 Less batch to batch variation 
 Water free production possible 
Demerits: 
 High energy technique 
 Suspension formation need 
 Micronized drug particles needed 
 Piston gap homogenizer: The drug is dispersed in 
an aqueous surfactant solution which is then forced 
by a piston through tiny homogenisation gap under 
high pressure. 
 Micro fluidizer technology: The principle is based 
on jet steaming. Two stream of liquid with high 
velocity collide frontally under high pressure. The 
particle size is reduced due to high shear force 
particle collision and cavitation. The collision 
chamber can be either Y-type or Z-type in shape. 
Surfactants or phospholipids are required to 
stabilize the desired particle size.
18,19
 
 Bottom up method: Oldest technique to prepare 
drug nanocrystals.Also known as Precipitation 
method. In this method, drug is dissolved in a 
solvent system which is miscible with the anti 
solvent. Mostly, water is used as anti-solvent.The 
preparation process involves two steps 
Step 1: Preparation of drug solution in organic 
solvents: Concentration of drug solution was prepared 
by preparing solution of drug in organic solvent (based 
on solubility of drug in particular solvent). 
Step 2: Addition of drug solution in water: The above 
prepared drug solution was added into required quantity 
of water containing polymeric stabilizers (PVP K30, 
Poloxamer 188, Poloxamer 407, combination of PVP 
K30 and Poloxamer 407 and combination of PVP K30 
and Poloxamer 188) with continuous stirring. 
Immediately, particles precipitated from the antisolvent 
and a milk-like suspension formed which was then 
filtered and dried. Drying was carried out using tray 
dryer at 40°c  
With the improvement in bottom-up technology, several 
other technology were developed based on precipitation 
method such as RESS and SAS techniques supercritical 
fluids are used as solvent or anti-solvent depend on the 
drug’s solubility. EPAS technique was developed for 
which are soluble in water immiscible solvents. 
Examples of products manufactured by the precipitation 
method are: Hydrosols and NanomorphTM, which are 
developed by Sucker and Soliqs/Abbott respectively 
Process parameter: Nature of solvent and antisolvent, 
Rate of addition of solvent to antisolvent, Ratio of 
solvent to antisolvent, Drug concentration in solvent, 
Type and amount of stabilizeretc 
Merits: 
 Ultrafine particles (<100 nm) can be obtained 
 Low cost 
 finely dispersed drug 
 Involve the controlled precipitation/crystallization 
of drug from its solution state 
Demerits: 
 Subsequent particle growth which affect the solid 
state stability of nanocrystals 
 Poor redispersibility 
 Residual solvent content19,20,21,22 
 Supercritical Fluid Crystallization: Supercritical 
fluid (SCF) existing at temperatures above their 
critical temperature and pressures beyond their 
critical pressure has low density, viscosity and high 
diffusivity. Most processes involve carbon dioxide 
as the SCF because it is nontoxic, nonflammable 
and inexpensive. This method could be classified 
by the principle of either the SCF fluid is used as 
solvent or anti-solvent. In this process, the 
supercritical fluid can be rapidly removed without 
lengthy drying.
23,24
 
 Rapid Expansion of Supercritical Solutions 
(RESS): This process is also known as 
supercritical fluid nucleation (SFN), which can be 
used for API that exhibits an efficient solubility in 
supercritical carbon dioxide (SCO2). The API is 
firstly dissolved in SCO2 in a high pressure vessel. 
The solution is then depressurized through a nozzle 
into the ambient environment, which results in the 
formation of the nanocrystals.
25,26
 
 Spray Drying: Spray drying is the most widely 
used and studied solvent evaporation method. In 
spray drying, the colloidal particles or sols are 
typically used as precursors. Then the fine droplets 
are evaporated in a warm air current to form dry 
particles. This method has been commonly used 
for the production of microparticles and solid lipid 
nanoparticles (SLNs) but still has limits to 
formulate nanocrystals.
25,26
 
 Combination technology: Combination technology 
is developing to overcome the problems of the top 
down and bottom up methods. This method is the 
combination of top down and bottom up methods. 
This technology is the two step process. 
First step pre- treatment process (bottom up) and 
second step is reduction of the particle size.   In second 
step, high pressure homogenization is used. This process 
is known as annealing. Annealing is the process of 
converting the unstable matter into the stable form by 
single or repeated application of energy, followed by 
thermal relaxation. The nanocrystals generated using 
combination technology has particle size below 200 nm. 
Nowadays, five combinative methods are known 
- NANOEDGE  
- H42 
- H69 
- H96
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NANO EDGE technology 
The drug is first dissolved in a suitable solvent, usually a water-miscible organic solvent 
                                                                  
     The drug solution is then mixed with a second aqueous liquid in which the drug is less soluble 
 
  The aqueous liquid can contain surfactants for stabilization, and it is added to the drug solution in a controlled manner  
       
The precipitation occurs due to the change in solubility 
 
         The microprecipitation is a pretreatment and drug particles can be obtained in amorphous or semicrystalline form. 
          
The drug particles are reduced in size by employing HPH. 
 
The residues of organic solvents in the nanosuspension 
are a major problem associated with this combinative 
technology, which becomes more complicated in the 
case of large-scale production (i.e., larger amounts of 
solvent to be removed from the final drug product). 
H42 technology: 
In this technology, spray drying (SD) is the first unit 
operation, the poorly soluble compound is dissolved in 
organic solvents. Surfactants such as poloxamer or 
sugars such as mannitol can be added to the drug 
solution to improve the results of the drying step. The 
obtained spray-dried drug powders are then dispersed in 
aqueous media containing surfactants for stabilization 
purposes. The suspensions are further processed to 
nanosuspensions by employing the HPH technique. 
H69 Technology: 
It combines amicroprecipitation step involving organic 
solvents, followed by high pressure homogenization for 
particle size reduction. To employ this combinative 
technique, the drug is dissolved in a suitable solvent, 
which is then mixed with an aqueous nonsolvent . The 
nonsolvent is added to the solvent in a controlled 
manner.The liquid flows come in contact, which results 
in the precipitation of the drug. The particle formation 
takes place in the high-energy zone of a homogenizer, 
where the just-formed drug particles are immediately 
treated with cavitation, particle collision, and shear 
forces.
22, 23, 24, 25 
 
 
 
 
 
 
 
 
Nanocrystal based formulations 
 
Figure 6: Formulations of nanocrystals 
Route of administration for nanocrystals  
 
Figure 7: Route of administration 
Applications of nanocrystals in drug delivery 
Formulations 
Suspension 
Capsules 
Pellets 
Powder 
for 
inhalation 
Emulsion 
Tablets 
Routes of 
administration 
Oral 
Parenteral 
Ocular Dermal 
Pulmonary 
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 Oral delivery: Oral administration is the most 
popular approach for drug delivery system due to its 
safety and convenience, especially for poorly 
soluble drugs. The performance of oral drugs is 
determined by their solubility in digestive juice and 
circulation in gastrointestinal tract.
27 
An oral 
controlled release formulation in combination with 
nanocrystal technology proved to be extremely 
beneficial especially for poorly soluble drugs. The 
combined technology enhances the flexibility of 
dosage form, quenching the need of alternative drug 
forms (like salt, prodrug etc), high drug loading and 
optimizing drug delivery. Besides, improved dose 
proportionality and reduction of fed/fast effect was 
also observed. Elan Drug Technologies have 
commercially introduced various products using 
this combined technology.
28,29
 
 Ocular drug delivery: Ocular drug delivery 
looking at the potential benefits of nanocrystals in 
oral drug delivery, their application is also explored 
for ocular drug delivery by several researchers 
includes detailed application of nanocrystal in 
ocular drug delivery. Not a single nanocrystal-based 
product is available in market for treatment of 
ocular diseases. This may be due to existence of 
patent on the use of production techniques for the 
development of nanocrystals. Research has proved 
the advantages of nanocrystals in ocular drug 
delivery which establish hope for the treatment of 
various ocular diseases as well as development of 
better alternative formulation for poorly soluble. 
 Improved ocular safety 
 Enhanced corneal permeation 
 Enhanced ocular bioavailability 
 Dual drug release behavior in the eye 
 Improved tolerability28,29,30 
 Dermal drug delivery: Dermal delivery of 
nanocrystals was a route of administration that was 
not fully exploited until relatively recently, despite 
the advantages of nanocrystals, such as adhesion, 
fast dissolution, and increased penetration, that can 
be useful for dermal application. The development 
of nanocrystals for delivery to the skin was first 
exploited in the field of cosmetics and it was later 
expanded for drug delivery purposes. Specifically, 
the cosmetic products Juvedical 1 (Juvena of 
Switzerland, Juvena Marlies Mo¨ller AG) and 
Platinum Rare collection (La Prairie 1) contain 
nanocrystals of the antioxidants rutin and 
hesperidin, respectively.
29,30,31
 
 Parenteral drug delivery: Implementation of 
nanocrystal technology enhances the performance 
of the parenterally injected poorly soluble drugs. It 
replaces organic solvents by aqueous-based 
solvents, reduces dose volume by improving drug 
loading, faster dissolution (due to nano size) and 
avoiding macrophage uptake. From a safety point of 
view, nanocrystals permit sterile filtering; also 
avoid use of any harsh excipients.
31,32
 
 Pulmonary drug delivery: For an optimal 
pulmonary drug delivery, particles with appropriate 
aerodynamic size, shape and density are the 
stringent requirements as the maximum particle size 
for central airways deposition is approximately 5 
µm. Generally, jet milled suspension aerosols or dry 
powders (usually micron sized) have been used for 
pulmonary delivery but often show below par 
performance that includes poor flow ability, low 
bioavailability (due to limited diffusion attributed to 
micro particulate nature of drugs), and unwanted 
deposition in mouth & pharynx. Nanocrystal 
technology offers preferential deep lung delivery of 
drugs either for systemicor local effect and 
exploiting nanosuspension is an ultimate and 
attractive approach in this regard.
32
 Moreover, it is 
suitable for use with ultrasonic and compressed air 
nebulizers with faster nebulization times. It is 
applicable to a wide range of drug molecules for 
inhalation either in the form of liquid droplets or 
powder.
33,34,35
 
 
Characterization parameters  
S.No. Characterization parameters  Methods  
1.  Mean particle size and size distribution Transmission Electron Microscopy(TEM), Scanning 
Electron Microscopy (SEM), Environmental Scanning 
Electron Microscopy (ESEM  
 
2. Structure and morphology  
 
Light microscopy, Scanning electron microscopy, 
transmission, Electron microscopy, Field emission 
scanning electron microscopy, Atomic force microscopy  
3. Surface charge  Zeta potential  
4. Rheological properties(for liquid nano 
suspensions) 
Viscometer, rheometer  
 
5. Solid state analysis(crystalline Powder X-ray diffraction, Differential scanning 
calorimetry  
6. Solubility UV spectrophotometer 
7. Concentration determination  Fluorescence spectroscopy  
Kaur et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2018; 8(5):118-129          
ISSN: 2250-1177                                                                             [128]                                                                             CODEN (USA): JDDTAO 
Nanocrystalline-based products approved by the FDA 
Trade 
name 
Company Active substance Indication Particle size 
reduction 
method 
Route Dosage 
form 
Year 
Avinza
® 
King Pharma Morphine sulfate Pain medication WMM  Oral Capsule  2002 
Azopt® Alcon Brinzolamide Ocular 
hypertension 
WMM Ocular Suspension 1998 
Cesamet® Lilly Nabilone Antiemetic Precipitation Oral Capsule 2005 
Emend® Merck Aprepitant Antiemetic WMM Oral Capsule 2003 
Focalin 
XR® 
Novartis Dexmethylphenida
te HCl 
ADHD WMM Oral Capsule 2001 
Gris-Peg® Novartis Griseofulvin Antifungal Precipitation Oral Tablet 1982 
Herbesser
® 
Mitsubishi Diltiazem Hypertension WMM Oral Tablet 2002 
Invega 
Sustenna
® 
Johnson & 
Johnson 
Paliperidone 
palmitate 
Antipsychotic WMM Intramu
scular 
Suspension 
in prefilled 
syringe 
2009 
Megace 
ES® 
Par 
Pharmaceutic
al 
Megestrol acetate Appetite stimulant WMM Oral Suspension     2005 
Naprelan® Wyeth Naproxen sodium NSAID WMM Oral Tablet 2006 
Rapamune
® 
Wyeth Sirolimus 
(rapamycin) 
Immunosuppressa
nt 
WMM Oral Suspension, 
tablet 
2000 
Ritalin 
LA® 
Novartis Methylphenidate 
HCl 
ADHD WMM Oral Capsule 2002 
Theodur® Mitsubishi 
Tanabe 
Pharma 
Theophylline Asthma, COPD WMM Oral Tablet, 
Capsule 
2008 
Tricor ® Abbott   Fenofibrate Hypercholesterole
mia 
WMM Oral Tablet 2004 
Triglide® SkyePharma Fenofibrate Hypercholesterole
mia 
HPH Oral Tablet 2005 
Verelan  ® Schwarz 
Pharma 
Verapamil HCl Hypertension WMM Oral Capsule 1998 
Zanaflex® Acorda Tizanidine HCl Muscle relaxant WMM  Oral Capsule 2002 
 
CONCLUSION  
Nanocrystal technology is evidently suitable for drugs 
with poor solubility. Drug nanocrystals can be applied to 
all poorly soluble drugs to overcome their solubility and 
bioavailability problems. The decrease in particle size to 
nanometer range contributes to the increased particle 
surface, curvature, saturation solubility, dissolution 
velocity and further acceptable bioavailability. Various 
applied and combination technologies are developed for 
the production of drug nanocrystals. At present, drug 
nanocrystals are paid increasing more attention as a 
promising approach owing to many reasons such as an 
increasing number of poorly soluble drugs in drug 
development process, pharmacoeconomic value, easier 
production, safer composition and other advantages that 
are previously mentioned. 
 
FUTURE PROSPECTS 
 Compared with traditional nanocarriers, the advantages 
of nano- crystals in physical stability, high drug loading 
and relative ease of production bring attractive 
alternatives for delivery of poorly soluble drugs. The use 
of drug nanocrystals is a universal formulation approach 
to increase the therapeutic performance of these drugs in 
any route of administration. Almost any drug can be 
reduced in size to the nanometer range. Most of the 
research has focused on the discovery of novel 
technologies for producing nano-crystals. These 
technologies have been patented both by drug delivery 
and pharmaceutical companies. As a result, wide 
selections of technologies are now available in the 
market. The research on nano-crystals is currently 
focused on the mechanistic understanding of 
drug/stabilizer interactions to provide a scientific 
framework for the selection of stabilizers. 
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